BioCatch stock
Private-market facts for current and former BioCatch employees researching their stock.
Overview
BioCatch provides behavioral biometric intelligence technology that analyzes user interactions like mouse movements and typing patterns to detect fraud, social engineering, and account takeover in real time for financial institutions.
BioCatch outlook
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling BioCatch shares
Why shareholders consider selling
Shareholders in BioCatch may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, BioCatch does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell BioCatch stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Cybersecurity sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing BioCatch shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of BioCatch shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Cybersecurity market conditions, and any recent private-market transaction activity.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for BioCatch shareholders
Exploring equity in BioCatch often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
BioCatch's latest funding details have not been publicly disclosed.
Lead investors in this round include Bain Capital Tech Opportunities and Maverick Ventures.
Founders & company background
BioCatch was founded in 2011 by Avi Turgeman, Uri Rivner, Benny Rosenbaum and is headquartered in Tel Aviv, Israel.
Investors
Industry
Similar private companies
Latest BioCatch news
Frequently asked questions
- Is BioCatch still a private company?
- Yes, BioCatch is currently a private company.
- What is BioCatch's latest funding round?
- The latest funding round has not been publicly disclosed.
- What is BioCatch's valuation?
- BioCatch's valuation has not been publicly disclosed.
- Who are the investors in BioCatch?
- Notable investors include Bain Capital Tech Opportunities, Maverick Ventures.
- Can I sell my BioCatch stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands BioCatch stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · BioCatch data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.